AIM ImmunoTech Inc.

Day range

$0.15 – $0.16

Open

$0.15

Prev close

$0.15

Volume

615.01K

Market cap

$6.18M

Shares out

39.89M

P/E

—

P/S

62.99

P/B

0.77

P/FCF

—

ROE

-225.6%

ROA

-137.2%

Debt/Equity

0.47

Div yield

0.00%

As of Nov 5, 2026

• Investor presentationNov 5, 2026

  Furnished herewith as Exhibits 99.1 and 99.2, respectively, are a Corporate Presentation of AIM ImmunoTech Inc. (the "Company") titled "The Ampligen Opportunity" and a press release issued by the Company on November 5, 2026.

• Warrant or conversionSep 14, 2026

  Pursuant to the Exchange Agreements and Partitioned Promissory Notes, the Company and the Lender converted approximately $400,000 of the Promissory Note into 1,749,434 shares (the “Exchange Shares”) of the Company's common stock, at an average conversion price of approximately $0.228 per share. The Exchange Shares were or will be issued pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended, provided by Section 3(a)(9) thereof.

• Warrant or conversionSep 10, 2026

  Pursuant to the Exchange Agreements and Partitioned Promissory Notes, the Company and the Lender converted approximately $450,000 of the Promissory Note into 1,921,441 shares (the "Exchange Shares") of the Company's common stock, at an average conversion price of approximately $0.234 per share.

• Debt retirementSep 4, 2026

  Consequently, as of September 3, 2026, the Promissory Note was satisfied in full and there are no longer any amounts owing under the Promissory Note.

• Director nominationAug 6, 2026

  Stockholders who wish to nominate a director at the Company's 2026 annual meeting of stockholders (the "2026 Annual Meeting"), or to bring any other proposal before the 2026 Annual Meeting, that is not to be included in this year's proxy materials pursuant to Rule 14a-8, must do so in accordance with the Company's Restated and Amended Bylaws, which require notice be received by the Secretary at the Company's principal executive offices not later than 5:00 p.m. local time on September 17, 2026 and not earlier than August 18, 2026.

Days to cover

1.5

Short interest

1.08M

Avg volume

737.51K

As of Oct 15, 2026 · reported to FINRA twice monthly.

• AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041
  positiveGlobeNewswire Inc.· Sep 2, 2026
• AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
  neutralGlobeNewswire Inc.· May 20, 2026
• AIM ImmunoTech Provides Routine Update on Annual Filings
  negativeGlobeNewswire Inc.· Apr 13, 2026
• Why Is AIM ImmunoTech Stock Gaining Today?
  positiveBenzinga· Mar 18, 2026
• AIM ImmunoTech Announces Closing of its Rights Offering
  neutralGlobeNewswire Inc.· Mar 6, 2026